Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy.
The usefulness of estramustine phosphate (ECT) for preventing flare-up in goserelin acetate depot therapy for advanced prostate cancer was studied. Pretreatment with ECT 560 mg daily for 3 weeks almost completely prevented the rise in testosterone level seen in goserelin acetate depot therapy and no signs or symptoms of tumor flare were observed. Long-term ECT completely blocked the rise in luteinizing hormone and testosterone level, but ECT at this dosage was likely to cause complications. The administration of ECT 560 mg daily for 3 weeks prior to goserelin acetate depot therapy was considered sufficient to prevent tumor flare, and its effect was considered to be more marked than that of short-term treatment with antiandrogens.
Shimizu
T S
TS
Department of Urology, Gunma Cancer Center, Ota, Japan.
Shibata
Y
Y
Jinbo
H
H
Satoh
J
J
Yamanaka
H
H
D000135:Acid Phosphatase / Q000097:blood / Q000187:drug effects; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000097:blood* / Q000473:pathology / Q000517:prevention & control; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000627:therapeutic use*; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000517:prevention & control; D013739:Testosterone / Q000097:blood
D017273:Goserelin; D004961:Estramustine; D013739:Testosterone; D007986:Luteinizing Hormone; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen